Pharmacotherapeutic effects of a Plant- derived Stem Cell (PDSC) in Fructose-fed Streptozotocin-induced diabetic Wistar rats


Trends in Natural Products Research


Pharmacotherapeutic effects of a Plant- derived Stem Cell (PDSC) in Fructose-fed
Streptozotocin-induced diabetic Wistar rats

Ifedolapo Adesola Adejumo1*, Muyiwa Samuel Fageyinbo2, Sikiru Olatunji Usman1, Okwara Onyebuchi Success1, Uwawuike Nkechi Amanda1, Olosunde Tolulope Oluwaseun1, Ibrahim Adekunle Oreagba1, Esther Oluwatoyin Agbaje1

  1. Department of Pharmacology, Therapeutics and Toxicology, College of Medicine, University of Lagos, Lagos, Nigeria
  2. Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, University of Medical Sciences, Ondo City, Ondo State, Nigeria.

 

Key words:

 Plant-derived stem cells, Type 2 diabetes mellitus, Insulin resistance, Fructose feeding, Streptozotocin.

 

*Corresponding Author: ifedolapokayode@gmail.com
DOI:https://doi.org/10.61594/tnpr.v7i2.2026.167

 

Page No: 187–207
Volume: 7, Issue 2, 2026
Trends in Natural Products Research
Copy Right: NAPREG

 

 

 

Abstract


Preventing type 2 diabetes mellitus (T2DM) requires lifestyle modification and early intervention; however, interest in alternative therapeutic options such as plant-derived stem cells (PDSC) is increasing, despite limited supporting evidence. This study investigated the pharmacotherapeutic effects of PDSC in fructose-fed, streptozotocin (STZ)-induced diabetic rats. Rats were pretreated with PDSC or distilled water (DW) for seven days prior to diabetes induction using 20% fructose and STZ (40 mg/kg, i.p.). Following induction, diabetic rats (n = 5 per group) were assigned to seven groups and treated with DW, glibenclamide (5 mg/kg), or PDSC (50, 100, or 200 mg/kg) orally for 28 days. Fasting blood glucose (FBG) was assessed at 7-day intervals. Hematological and biochemical parameters were evaluated alongside glycosylated hemoglobin (HbA1c), serum insulin, and the insulin resistance index (HOMA-IR). Thigh skeletal muscle was harvested for glucose transporter 4 (GLUT-4) assay, the liver for glycogen estimation, and both the liver and pancreas for antioxidant analysis. Diabetic control rats showed a significant increase in FBG (361.70 ± 46.93 mg/dL) compared with normal controls (89.00 ± 1.29 mg/dL). Treatment with PDSC at 50, 100, and 200 mg/kg significantly (P < 0.05) reduced FBG by 51.42%, 68.21%, and 59.51%, respectively, while glibenclamide achieved a 73.68% reduction. PDSC treatment significantly increased serum insulin, hepatic glycogen, and GLUT-4 levels, and reduced HbA1c and HOMA-IR, indicating improved insulin sensitivity. No significant alterations were observed in hematological or biochemical parameters. Additionally, PDSC significantly (P < 0.05) increased catalase (CAT), superoxide dismutase (SOD), and reduced glutathione (GSH) levels, while decreasing malondialdehyde (MDA) concentrations in the liver and pancreas. These findings suggest that PDSC exhibits promising anti-type 2 diabetic activity.